Postmenopausal osteoporosis

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 6, 2013, Pages 501-509

  Diab, Dima L ^a   Watts, Nelson B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Mercy Health Osteoporosis and Bone Health Services   (United States)

Author keywords

Diagnosis; Fractures; Postmenopausal osteoporosis; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; CALCITONIN; CALCIUM; COLECALCIFEROL; CREATININE; CYCLOSPORIN; DENOSUMAB; ERGOCALCIFEROL; ESTROGEN; GLUCOCORTICOID; HEPARIN; IBANDRONIC ACID; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; RALOXIFENE; RETINOL; RISEDRONIC ACID; SALCATONIN; SEROTONIN UPTAKE INHIBITOR; SODIUM; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANDROGEN DEPRIVATION THERAPY; ANOREXIA NERVOSA; APOPTOSIS; BLOOD CELL COUNT; BODY EQUILIBRIUM; BONE DENSITOMETRY; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CALCIUM DEFICIENCY; CALCIUM INTAKE; CALCIUM URINE LEVEL; CARDIOVASCULAR DISEASE; CATARACT EXTRACTION; CHRONIC LIVER DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CUSHING SYNDROME; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EHLERS DANLOS SYNDROME; ENTERITIS; FALL RISK; FEMUR FRACTURE; FEMUR NECK; FEMUR SUBTROCHANTERIC FRACTURE; FOLLOW UP; FOREARM; FRACTURE REDUCTION; FRAGILITY FRACTURE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE; HEARING; HEMOCHROMATOSIS; HIP; HIP FRACTURE; HOMOCYSTINURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERCALCIURIA; HYPERPARATHYROIDISM; HYPERTHYROIDISM; HYPOGONADISM; HYPOPHOSPHATASIA; IMMOBILIZATION; INCIDENCE; INTERMETHOD COMPARISON; JAW OSTEONECROSIS; KIDNEY FAILURE; LEUKEMIA; LUMBAR SPINE; MALABSORPTION; MALNUTRITION; MARFAN SYNDROME; MASTOCYTOSIS; META ANALYSIS (TOPIC); MORTALITY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; MUSCLE TRAINING; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; ORGAN TRANSPLANTATION; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PAGET BONE DISEASE; PAIN; PARESTHESIA; PATIENT PREFERENCE; PORPHYRIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; SECONDARY OSTEOPOROSIS; SICKLE CELL ANEMIA; SMOKING; SOFT TISSUE DISEASE; SOFT TISSUE ULCERATION; SPINE; SPINE FRACTURE; STOMACH SURGERY; STRESS FRACTURE; SUPPURATION; SWELLING; SYSTEMATIC REVIEW (TOPIC); THALASSEMIA; THROMBOEMBOLISM; TOOTH EXTRACTION; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; VISION; VISUAL IMPAIRMENT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WEIGHT BEARING; WEIGHT REDUCTION;

ACCIDENTAL FALLS; AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CALCIUM; DIETARY SUPPLEMENTS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TERIPARATIDE; VITAMIN D;

EID: 84890126528     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/01.med.0000436194.10599.94     Document Type: Review

References (80)

1. NIH Consensus Statement. Osteoporosis prevention, diagnosis, and therapy. 2000; 17:1-45.
2. Iwamoto J, Sato Y, Takeda T, Matsumoto H. Whole body vibration exercise improves body balance and walking velocity in postmenopausal osteoporotic women treated with alendronate: Galileo and Alendronate Intervention Trail (GAIT). J Musculoskelet Neuronal Interact 2012; 12:136-143.
3. Diab DL, Watts NB. Diagnosis and treatment of osteoporosis in older adults. Endocrinol Metab Clin North Am 2013; 42:305-317. This article provides a thorough updated review focusing on the treatment of elderly subjects with osteoporosis.
4. U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011; 154:356-364.
5. Diab DL, Watts NB. Secondary osteoporosis: differential diagnosis and workup. Clin Obstet Gynecol 2013. [Epub ahead of print]
6. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010; 16 (Suppl 3):1-37.
7. Cerda Gabaroi D, Peris P, Monegal A, et al. Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 2010; 17:135-139.
8. Hudec SM, Camacho PM. Secondary causes of osteoporosis. Endocr Pract 2013; 19:120-128. This article provides an updated review of several causes of secondary osteoporosis as well as screening recommendations for these disorders.
9. Swaminathan K, Flynn R, Garton M, et al. Search for secondary osteoporosis: are Z scores useful predictors?. Postgrad Med J 2009; 85:38-39.
10. McKiernan FE, Berg RL, Linneman JG. The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis. Osteoporos Int 2011; 22:1069-1077.
11. Yung CK, Fook-Chong S, Chandran M. The prevalence of recognized contributors to secondary osteoporosis in South East Asian men and postmenopausal women. Are Z score diagnostic thresholds useful predictors of their presence? Arch Osteoporos 2012; 7:49-56. This manuscript emphasizes the importance of not solely relying on z score diagnostic thresholds to discriminate between primary and secondary osteoporosis.
12. Prentice RL, Pettinger MB, Jackson RD, et al. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int 2013; 24:567-580. This study examines the health benefits and risks of calcium and vitamin D supplementation using WHI data, with emphasis on fractures, cardiovascular disease, cancer, and total mortality.
13. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657-666.
14. Verbrugge FH, Gielen E, Milisen K, Boonen S. Who should receive calcium and vitamin D supplementation?. Age Ageing 2012; 41:576-580.
15. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367:40-49. This is a large analysis of 11 double-blind, randomized, controlled trials of oral vitamin D looking at the effect of vitamin D supplementation on fracture risk reduction.
16. Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012; 33:456-492. This article reviews both the basic and clinical aspects of vitamin D in relation to nonskeletal organ systems.
17. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911-1930.
18. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012; 97:1153-1158. This manuscript summarizes the current evidence and guidelines for preventing and treating vitamin D deficiency.
19. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93:677-681.
20. Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr 2012; 95:1357-1364. This is a large review and meta-analysis comparing vitamin D2 and D3 effectiveness in adults.
21. Grundstrom AC, Guse CE, Layde PM. Risk factors for falls and fall-related injuries in adults 85 years of age and older. Arch Gerontol Geriatr 2012; 54:421-428.
22. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012; 9:CD007146. This is an update of a Cochrane review first published in 2009, which assesses the effects of interventions designed to reduce the incidence of falls in older people living in the community.
23. Waldron N, Hill AM, Barker A. Falls prevention in older adults - assessment and management. Aust Fam Physician 2012; 41:930-935.
24. Curtis JR, Safford MM. Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging 2012; 29:549-564.
25. Chesnut CH 3rd, Silverman S, Andriano K, et al., PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109:267-276.
26. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 1999; 282:637-645.
27. Foster SA, Shi N, Curkendall S, et al. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health 2013; 13:15. This is the first retrospective cohort study evaluating fracture and breast cancer rates among patients treated with raloxifene or alendronate.
28. Chung YE, Lee SH, Lee SY, et al. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 2012; 23:1235-1243. This study provides insight into the mechanism of action of estrogen on bone metabolism.
29. Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am 2012; 41:487-506. This article provides a thorough updated review of the use of bisphosphonates in the treatment of osteoporosis.
30. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZONPivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27:243-254. This is a landmark international, multicenter, double-blind, placebo-controlled extension trial assessing the risks and benefits of stopping zoledronic acid therapy at 3 years versus continuing treatment up to 6 years.
31. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75:462-468.
32. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Longterm Extension (FLEX): a randomized trial. Jama 2006; 296:2927-2938.
33. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010; 25:976-982.
34. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-1491.
35. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012; 27:2544-2550. This study provides new information on the risk of AFFs with long-term bisphosphonate use.
36. Shane E, Ebeling PR, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2013. [Epub ahead of print]. doi: 10.1002/jbmr.1998. This updated report summarizes the data currently available on AFFs and reviews studies on the epidemiology, pathogenesis, and medical management of AFFs published since 2010.
37. Meier RP, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172:930-936. This is another study providing new information on the risk of AFFs with long-term bisphosphonate use.37
38. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. J Bone Miner Res 2013; 28:1729-1737. This large meta-analysis also assesses the risk of AFFs with bisphosphonate use.
39. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis-where do we go from here? N Engl J Med 2012; 366:2048-2051.
40. Diab DL, Watts NB. Use of drug holidays in women taking bisphosphonates. Menopause 2013. [Epub ahead of print] This article summarizes our expert opinion regarding bisphosphonate drug holidays in postmenopausal women based on the current evidence.
41. Compston JE, Bilezikian JP. Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res 2012; 27:240-242.
42. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012; 97:2272-2282.
43. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126:13-20.
44. Josse R, Khan A, Ngui D, et al. a new pharmacotherapy option for postmenopausal osteoporosis. Curr Med Res Opin 2013; 29:205-216. This is a recent thorough review of the use of denosumb in osteoporosis.
45. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012; 27:694-701. This is an important study reporting the extension results of the FREEDOM trial and assessing the risk/benefit profile of denosumab with continued therapy up to 5 years.
46. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011; 96:1727-1736.
47. McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012; 27:211-218.
48. Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int 2012; 23:327-337. This paper provides a thorough review of serious adverse events of infections that occurred in subjects receiving denosumab or placebo in the FREEDOM trial.
49. Paparodis R, Buehring B, Pelley E, Binkley N. A Case of an Unusual Subtrochanteric Fracture in a Patient Receiving Denosumab. Endocr Pract 2013; 19:e64-e68.
50. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
51. Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009; 94:3772-3780.
52. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013; 382:50-56. This is the first randomized study comparing the effects of teriparatide and denosumab alone or combined in postmenopausal women with osteoporosis.
53. Subbiah V, Madsen VS, Raymond AK, et al. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 2010; 21:1041-1045.
54. Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 2012; 27:2419-2428. This article provides an updated review of the safety of osteoanabolic therapy.
55. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012; 27:2429-2437.
56. Yoshiga D, Yamashita Y, Nakamichi I, et al. Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 2013; 24:2365-2369. This report describes a potential off-label benefit (ONJ) for teriparatide use.
57. Chiang CY, Zebaze RM, Ghasem-Zadeh A, et al. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 2013; 52:360-365. This article describes another potential off-label benefit (AFF) for teriparatide use.
58. Boonen S, Rosenberg E, Claessens F, et al. Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep 2012; 10:73-79. This review describes the potential usefulness of cathepsin K inhibitors in treating postmenopausal women with osteoporosis.
59. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 2012; 27:2251-2258. This study reports the results of 5 years of odanacatib therapy, an emerging therapeutic option in the treatment of postmenopausal osteoporosis.
60. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 2013; 98:571-580. This is the first randomized trial examining the effect of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine in postmenopausal women.
61. Zerbini CA, McClung MR. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. Ther Adv Musculoskelet Dis 2013; 5:199-209. This is a recent review of the use of odanacatib in postmenopausal women with osteoporosis.
62. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33:747-783. This article provides a thorough review of the effects of sclerostin and DKK-1 on bone, along with the therapeutic potential of using antibodies targeted at these compounds.
63. Lewiecki EM. Monoclonal antibodies for the treatment of osteoporosis. Expert Opin Biol Ther 2013; 13:183-196. This manuscript reviews the use of monoclonal antibodies in the treatment of osteoporosis.
64. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010; 95:151-158.
65. Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis. Endocrinol Metab Clin North Am 2012; 41:507-525. This is a thorough review of the use of osteoanabolic therapies for treating Osteoporosis
66. Henriksen K, Andersen JR, Riis BJ, et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone 2013; 53:160-166. This article evaluates a novel way of administering recombinant parathyroid hormone in treating postmenopausal osteoporosis.
67. Horwitz MJ, Augustine M, Kahn L, et al. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study. J Bone Miner Res 2013. [Epub ahead of print]. doi: 10.1002/jbmr. 1978. This study reports encouraging results with the use of PTHrP (as compared to PTH) in treating postmenopausal women with low bone density or osteoporosis.
68. Esbrit P, Alcaraz MJ. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol 2013; 85:1417-1423.
69. Abrahamsen B. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database. Osteoporos Int 2013; 24:369-372. This article highlights the fact that the prevalence of long-term bisphosphonate use may be low because of low refill compliance and gaps in treatment.
70. Ziller V, Kostev K, Kyvernitakis I, et al. Persistence and compliance of medications used in the treatment of osteoporosis-analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012; 50:315-322.
71. Weycker D, Lamerato L, Schooley S, et al. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Osteoporos Int 2013; 24:1483-1489. This retrospective cohort study emphasizes that better adherence with bisphosphonates appears to confer tangible benefits in terms of increases in BMD.
72. Sampalis JS, Adachi JD, Rampakakis E, et al. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 2012; 27:202-210.
73. Yu SF, Chou CL, Lai HM, et al. Adherence to antiosteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospitalbased study. Int J Rheum Dis 2012; 15:297-305.
74. Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007; 24:37-55.
75. Gold DT, Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 2006; 4:21-27.
76. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of noncompliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008; 24:1337-1344.
77. Barrett-Connor E, Wade SW, Do TP, et al. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US. Osteoporos Int 2012; 23:733-741. This article describes the association between treatment satisfaction and the risk of discontinuation/switching postmenopausal osteoporosis medications using patient-reported data from a large, longitudinal cohort study and emphasizes the importance of treatment satisfaction for persistence with therapy.
78. Crandall CJ, Newberry SJ, Diamant A, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. (Comparative Effectiveness Reviews, No. 53.) Available from: http://www.ncbi.nlm.nih.gov/books/NBK92566/.
79. Guanabens N, Monegal A, Cerda D, et al. A randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013. [Epub ahead of print]. doi: 10.1002/hep.26466. This study suggests that adherence is higher with the less frequent dosing regimen of bisphosphonates.
80. Sewerynek E, Horst-Sikorska H, Stepien-Klos W, et al. The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy. Arch Med Sci 2013; 9:288-296. This article assesses different interventions aimed at increasing compliance with alendronate therapy.